Vivus (VVUS +3.3%) rallies amidst speculation activist investor First Manhattan is set to win its proxy battle to replace the drug developer's entire board. TheStreet's Adam Feuerstein reports management gave off a "defeatist" vibe at a breakfast meeting. Vivus' shareholder meeting is on Monday. Analysts and #3 shareholder QVT Financial have backed First Manhattan; advisory firms ISS and Glass Lewis have backed Vivus.